- Home
- ONDS vs LYEL Comparison
ONDS vs LYEL Comparison
Compare ONDS & LYEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ONDS
- LYEL
- Stock Information
- Founded
- ONDS 2014
- LYEL 2018
- Country
- ONDS United States
- LYEL United States
- Employees
- ONDS N/A
- LYEL N/A
- Industry
- ONDS Telecommunications Equipment
- LYEL Biotechnology: Pharmaceutical Preparations
- Sector
- ONDS Telecommunications
- LYEL Health Care
- Exchange
- ONDS Nasdaq
- LYEL Nasdaq
- Market Cap
- ONDS 218.8M
- LYEL 203.9M
- IPO Year
- ONDS N/A
- LYEL 2021
- Fundamental
- Price
- ONDS $2.07
- LYEL $0.58
- Analyst Decision
- ONDS Buy
- LYEL Sell
- Analyst Count
- ONDS 1
- LYEL 2
- Target Price
- ONDS $4.00
- LYEL $1.00
- AVG Volume (30 Days)
- ONDS 11.0M
- LYEL 1.1M
- Earning Date
- ONDS 11-12-2024
- LYEL 02-26-2025
- Dividend Yield
- ONDS N/A
- LYEL N/A
- EPS Growth
- ONDS N/A
- LYEL N/A
- EPS
- ONDS N/A
- LYEL N/A
- Revenue
- ONDS $8,024,937.00
- LYEL $63,000.00
- Revenue This Year
- ONDS N/A
- LYEL N/A
- Revenue Next Year
- ONDS $279.95
- LYEL N/A
- P/E Ratio
- ONDS N/A
- LYEL N/A
- Revenue Growth
- ONDS N/A
- LYEL N/A
- 52 Week Low
- ONDS $0.54
- LYEL $0.55
- 52 Week High
- ONDS $3.40
- LYEL $3.26
- Technical
- Relative Strength Index (RSI)
- ONDS 52.50
- LYEL 34.70
- Support Level
- ONDS $1.82
- LYEL $0.55
- Resistance Level
- ONDS $2.27
- LYEL $0.62
- Average True Range (ATR)
- ONDS 0.42
- LYEL 0.04
- MACD
- ONDS -0.10
- LYEL 0.01
- Stochastic Oscillator
- ONDS 15.82
- LYEL 14.24
About ONDS Ondas Holdings Inc.
Ondas Holdings Inc designs, develops, manufactures, sells, and supports FullMAX Software Defined Radio (SDR) technology in the United States, Israel, and India. The company operates in two business segments namely Ondas Networks and Ondas Autonomous Systems. The company generates maximum revenue from Ondas Autonomous Systems through the sales of the Optimus system and separately priced support, maintenance, and ancillary services related to the sale of the Optimus system.
About LYEL Lyell Immunopharma Inc.
Lyell Immunopharma Inc is a clinical-stage cell therapy company. It has a pipeline of product candidates for patients with solid tumors utilizing ex vivo genetic and epigenetic T-cell reprogramming technologies. The company's product pipeline includes, LYL797, LYL119, LYL845 among others.